During the recent session, Nuvation Bio Inc (NYSE:NUVB)’s traded shares were 0.59 million, with the beta value of the company hitting 1.37. At the last check today, the stock’s price was $2.22, reflecting an intraday gain of 10.51% or $0.21. The 52-week high for the NUVB share is $4.16, that puts it down -87.39 from that peak though still a striking 57.21% gain since the share price plummeted to a 52-week low of $0.95. The company’s market capitalization is $743.65M, and the average intraday trading volume over the past 10 days was 1.64 million shares, and the average trade volume was 1.53 million shares over the past three months.

Nuvation Bio Inc (NUVB) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. NUVB has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.14.

Nuvation Bio Inc (NYSE:NUVB) trade information

Nuvation Bio Inc (NUVB) registered a 10.51% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 10.51% in intraday trading to $2.22, hitting a weekly high. The stock’s 5-day price performance is -7.83%, and it has moved by -27.41% in 30 days. Based on these gigs, the overall price performance for the year is 82.07%. The short interest in Nuvation Bio Inc (NYSE:NUVB) is 21.42 million shares and it means that shorts have 12.67 day(s) to cover.

The consensus price target of analysts on Wall Street is $6, which implies an increase of 63.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $10 respectively. As a result, NUVB is trading at a discount of -350.45% off the target high and -125.23% off the low.

Nuvation Bio Inc (NUVB) estimates and forecasts

Statistics show that Nuvation Bio Inc has underperformed its competitors in share price, compared to the industry in which it operates. Nuvation Bio Inc (NUVB) shares have gone down -25.21% during the last six months, with a year-to-date growth rate less than the industry average at -522.86% against 17.50. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -55.60% this quarter and then drop -133.30% in the quarter after that.

While earnings are projected to return -524.69% in 2024.

NUVB Dividends

Nuvation Bio Inc is due to release its next quarterly earnings on 2024-Oct-31. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Nuvation Bio Inc (NYSE:NUVB)’s Major holders

Nuvation Bio Inc insiders own 27.01% of total outstanding shares while institutional holders control 44.64%, with the float percentage being 61.15%. FMR LLC is the largest shareholder of the company, while 195.0 institutions own stock in it. As of 2024-06-30, the company held over 28.82 million shares (or 13.1578% of all shares), a total value of $84.16 million in shares.

The next largest institutional holding, with 19.21 million shares, is of ECOR1 CAPITAL, LLC’s that is approximately 8.7696% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $56.09 million.

Also, the Mutual Funds coming in first place with the largest holdings of Nuvation Bio Inc (NUVB) shares are Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund. Data provided on Aug 31, 2024 indicates that Fidelity Growth Company Fund owns about 9.11 shares. This amounts to just over 3.67 percent of the company’s overall shares, with a $20.18 million market value. The same data shows that the other fund manager holds slightly less at 6.13, or about 2.47% of the stock, which is worth about $13.57 million.